sharon sanders
Editor-in-Chief & President
[SIZE=+2]Cellular<SUP> </SUP>and<SUP> </SUP>Humoral<SUP> </SUP>Responses<SUP> </SUP>to<SUP> </SUP>Influenza<SUP> </SUP>in<SUP> </SUP>Gabonese<SUP> </SUP>Children<SUP> </SUP>Living<SUP> </SUP>in<SUP> </SUP>Rural<SUP> </SUP>and<SUP> </SUP>Semi-Urban<SUP> </SUP>Areas<SUP></SUP><SUP> </SUP>[/SIZE]
[FONT=helvetica, arial][SIZE=-1]E. van Riet,<SUP>1,</SUP><SUP>a</SUP><SUP> </SUP>A. A. Adegnika,<SUP>1,4,5</SUP><SUP> </SUP>K. Retra,<SUP>1,2</SUP><SUP> </SUP>R. Vieira,<SUP>1</SUP><SUP> </SUP>A. G. M. Tielens,<SUP>2</SUP>,<SUP> </SUP>B. Lell,<SUP>4,5</SUP><SUP> </SUP>S. Issifou,<SUP>4</SUP><SUP> </SUP>F. C. Hartgers,<SUP>1</SUP><SUP> </SUP>G. F. Rimmelzwaan,<SUP>3</SUP><SUP> </SUP>P. G. Kremsner,<SUP>4,5</SUP><SUP> </SUP>and<SUP> </SUP>M. Yazdanbakhsh<SUP>1,4</SUP><SUP> </SUP>[/SIZE][/FONT][FONT=helvetica, arial][SIZE=-1]<SUP>1</SUP>Department<SUP> </SUP>of<SUP> </SUP>Parasitology,<SUP> </SUP>Leiden<SUP> </SUP>University<SUP> </SUP>Medical<SUP> </SUP>Center,<SUP> </SUP>Leiden,<SUP> </SUP><SUP>2</SUP>Department<SUP> </SUP>of<SUP> </SUP>Biochemistry<SUP> </SUP>and<SUP> </SUP>Cell<SUP> </SUP>Biology,<SUP> </SUP>Faculty<SUP> </SUP>of<SUP> </SUP>Veterinary<SUP> </SUP>Medicine,<SUP> </SUP>Utrecht<SUP> </SUP>University,<SUP> </SUP>Utrecht,<SUP> </SUP>and<SUP> </SUP><SUP>3</SUP>Department<SUP> </SUP>of<SUP> </SUP>Virology<SUP> </SUP>and<SUP> </SUP>National<SUP> </SUP>Influenza<SUP> </SUP>Center,<SUP> </SUP>Erasmus<SUP> </SUP>Medical<SUP> </SUP>Center,<SUP> </SUP>Rotterdam,<SUP> </SUP>The<SUP> </SUP>Netherlands;<SUP> </SUP><SUP>4</SUP>Medical<SUP> </SUP>Research<SUP> </SUP>Unit,<SUP> </SUP>Albert<SUP> </SUP>Schweitzer<SUP> </SUP>Hospital,<SUP> </SUP>Lambar?n?,<SUP> </SUP>Gabon;<SUP> </SUP><SUP>5</SUP>Department<SUP> </SUP>of<SUP> </SUP>Human<SUP> </SUP>Parasitology,<SUP> </SUP>Institute<SUP> </SUP>for<SUP> </SUP>Tropical<SUP> </SUP>Medicine,<SUP> </SUP>T?bingen<SUP> </SUP>University,<SUP> </SUP>T?bingen,<SUP> </SUP>Germany<SUP> </SUP>[/SIZE][/FONT]
</B>
<CENTER><TABLE cellSpacing=0 cellPadding=0 width="80%" border=0><TBODY><TR><TD>
Background. With the current attention<SUP> </SUP>to the pandemic threat<SUP> </SUP>of avian influenza viruses,<SUP> </SUP>it is recognized that<SUP> </SUP>there is little information<SUP> </SUP>on influenza in Africa.<SUP> </SUP>In addition, the effects<SUP> </SUP>of influenza vaccination in<SUP> </SUP>African countries could be<SUP> </SUP>very different from the<SUP> </SUP>effects in regions with<SUP> </SUP>less exposure to microorganisms<SUP> </SUP>and parasites.
Methods. To monitor the<SUP> </SUP>presence of influenza viruses<SUP> </SUP>and investigate the immunological<SUP> </SUP>responses to influenza vaccination,<SUP> </SUP>schoolchildren in semi-urban and<SUP> </SUP>rural regions of Gabon<SUP> </SUP>were studied. Influenza-specific antibody<SUP> </SUP>responses to the 3<SUP> </SUP>strains represented in the<SUP> </SUP>vaccine were determined in<SUP> </SUP>the serum. Furthermore, cytokine<SUP> </SUP>responses were measured after<SUP> </SUP>in vitro stimulation of<SUP> </SUP>whole blood by influenza<SUP> </SUP>antigens, before and after<SUP> </SUP>vaccination.<SUP> </SUP>
Results. Prevaccination titers of antibody<SUP> </SUP>against H3N2 were high.<SUP> </SUP>At vaccination, the titers<SUP> </SUP>of antibody against the<SUP> </SUP>3 influenza strains increased<SUP> </SUP>significantly. The anti-H1N1 and<SUP> </SUP>anti-B responses after vaccination<SUP> </SUP>were weaker in rural<SUP> </SUP>schoolchildren than in semi-urban<SUP> </SUP>schoolchildren. Influenza-specific cytokine responses<SUP> </SUP>were induced within a<SUP> </SUP>week, showing significantly lower<SUP> </SUP>interferon-
Conclusions. Prevaccination antibody<SUP> </SUP>levels indicated that influenza<SUP> </SUP>viruses circulate in Gabon.<SUP> </SUP>Altogether, influenza vaccination induces<SUP> </SUP>weaker immune responses in<SUP> </SUP>a rural population than<SUP> </SUP>in a semi-urban population<SUP> </SUP>of Gabonese schoolchildren.<SUP> </SUP>
</TD></TR></TBODY></TABLE></CENTER><HR>
[SIZE=-1] Received 15 March 2007; accepted 31 May 2007; electronically published 22 October 2007.[/SIZE]<SUP> </SUP>
[SIZE=-1] Potential conflicts<SUP> </SUP>of interest: none reported.<SUP> </SUP>
Financial<SUP> </SUP>support: Dutch Organization for<SUP> </SUP>Scientific Research (ZonMW TOP<SUP> </SUP>programme grant 912-03-048 to<SUP> </SUP>M.Y. and F.C.H.); European<SUP> </SUP>commission (INCO programme grant<SUP> </SUP>CT2006-031714 to M.Y. and<SUP> </SUP>E.v.R.); Netherlands Foundation for<SUP> </SUP>the Advancement of Tropical<SUP> </SUP>Research (contract W95-367 to<SUP> </SUP>K.R.).<SUP> </SUP>[/SIZE]
[SIZE=-1] <SUP>a</SUP> Present affiliation: Division of<SUP> </SUP>Drug Delivery Technology, Leiden<SUP> </SUP>Amsterdam Center for Drug<SUP> </SUP>Research, Leiden, The Netherlands.<SUP> </SUP>[/SIZE]
[SIZE=-1] Reprints<SUP> </SUP>or<SUP> </SUP>correspondence:<SUP> </SUP>E.<SUP> </SUP>van<SUP> </SUP>Riet,<SUP> </SUP>Dept.<SUP> </SUP>of<SUP> </SUP>Parasitology,<SUP> </SUP>Leiden<SUP> </SUP>University<SUP> </SUP>Medical<SUP> </SUP>Center,<SUP> </SUP>P.O.<SUP> </SUP>Box<SUP> </SUP>9600,<SUP> </SUP>2300<SUP> </SUP>RC<SUP> </SUP>Leiden,<SUP> </SUP>The<SUP> </SUP>Netherlands<SUP> </SUP>(evanriet@lacdr.leidenuniv.nl).[/SIZE]
<HR> Little<SUP> </SUP>information is available on<SUP> </SUP>influenza in Africa. Influenza-surveillance<SUP> </SUP>capacity is weak on<SUP> </SUP>this continent, and only<SUP> </SUP>2 countries, South Africa<SUP> </SUP>and Senegal, engage in<SUP> </SUP>active monitoring of the<SUP> </SUP>infection and disease [1].<SUP> </SUP>Along with the global<SUP> </SUP>anxiety over the spread<SUP> </SUP>of H5N1 avian influenza,<SUP> </SUP>concerns have been raised<SUP> </SUP>about the lack of<SUP> </SUP>accurate data from the<SUP> </SUP>African continent [1http://www.journals.uchicago.edu/JID/journal/issues/v196n11/38547/38547.text.html#rf2http://www.journals.uchicago.edu/JID/journal/issues/v196n11/38547/38547.text.html#rf3?4]. In<SUP> </SUP>the few sporadic studies<SUP> </SUP>conducted in Africa, involving<SUP> </SUP>virological assessments, it appears<SUP> </SUP>that the problem of<SUP> </SUP>influenza virus is probably<SUP> </SUP>greatly underestimated. In the<SUP> </SUP>areas studied, the virus<SUP> </SUP>was found to be<SUP> </SUP>present and to either<SUP> </SUP>circulate throughout the year<SUP> </SUP>or peak seasonally [2].<SUP> </SUP>The reporting of influenza,<SUP> </SUP>based on clinical manifestations,<SUP> </SUP>is difficult in Africa,<SUP> </SUP>because symptoms are shared<SUP> </SUP>with many other infections<SUP> </SUP>that are prevalent in<SUP> </SUP>the region, making collection<SUP> </SUP>of data on morbidity<SUP> </SUP>and mortality particularly difficult.<SUP> </SUP>Such data are needed<SUP> </SUP>to trace the virus<SUP> </SUP>globally and also to<SUP> </SUP>identify people at the<SUP> </SUP>highest risk who would<SUP> </SUP>benefit from preventive vaccination.<SUP> </SUP>
Considering<SUP> </SUP>vaccination, we find that<SUP> </SUP>even less is known<SUP> </SUP>about the effectiveness of<SUP> </SUP>influenza vaccines in Africa.<SUP> </SUP>With the current attention<SUP> </SUP>to the pandemic threat<SUP> </SUP>of avian influenza viruses,<SUP> </SUP>its global spread, and<SUP> </SUP>the preparation of preventive<SUP> </SUP>and curative vaccines, it<SUP> </SUP>is important to start<SUP> </SUP>asking what the immunological<SUP> </SUP>consequences of influenza vaccination<SUP> </SUP>are in African populations.<SUP> </SUP>These vaccines are mostly<SUP> </SUP>developed and tested in<SUP> </SUP>Europe, in North America,<SUP> </SUP>and in some parts<SUP> </SUP>of Asia. It is<SUP> </SUP>known that vaccines that<SUP> </SUP>have performed well in<SUP> </SUP>populations living in high-income<SUP> </SUP>countries might perform less<SUP> </SUP>well in populations living<SUP> </SUP>in low-income countries [5,<SUP> </SUP>6].<SUP> </SUP>
The conditions found in<SUP> </SUP>the urban centers of<SUP> </SUP>Africa (those with high-<SUP> </SUP>to middle-income populations) might<SUP> </SUP>approximate those found in<SUP> </SUP>the urban centers of<SUP> </SUP>western and industrialized countries.<SUP> </SUP>However, the conditions (i.e.,<SUP> </SUP>lifestyle and exposure to<SUP> </SUP>infection) found in the<SUP> </SUP>rural areas of Africa<SUP> </SUP>vary widely. Many infectious<SUP> </SUP>diseases prevalent in Africa,<SUP> </SUP>particularly those present in<SUP> </SUP>rural areas and chronic<SUP> </SUP>in nature, are known<SUP> </SUP>to be associated with<SUP> </SUP>profound alternations of the<SUP> </SUP>innate [7http://www.journals.uchicago.edu/JID/journal/issues/v196n11/38547/38547.text.html#rf8?9] and the<SUP> </SUP>adaptive [10http://www.journals.uchicago.edu/JID/journal/issues/v196n11/38547/38547.text.html#rf11?12] immune system,<SUP> </SUP>which may affect responses<SUP> </SUP>to third-party antigens. For<SUP> </SUP>example, chronic helminth infections,<SUP> </SUP>which are highly prevalent<SUP> </SUP>in many rural areas<SUP> </SUP>of Africa, are known<SUP> </SUP>to be associated with<SUP> </SUP>the skewing of immune<SUP> </SUP>responses toward Th2 [13].<SUP> </SUP>Moreover, infections with some<SUP> </SUP>parasitic helminths and protozoa,<SUP> </SUP>along with mycobacterial, malarial,<SUP> </SUP>and viral hepatitis infections,<SUP> </SUP>have been shown to<SUP> </SUP>induce regulatory immune responses<SUP> </SUP>that are characterized by<SUP> </SUP>production of high levels<SUP> </SUP>of suppressory cytokines such<SUP> </SUP>as transforming growth factor?
To our<SUP> </SUP>knowledge, influenza surveillance has<SUP> </SUP>never been conducted in<SUP> </SUP>Gabon, and, because the<SUP> </SUP>symptoms of influenza infection<SUP> </SUP>closely resemble those of<SUP> </SUP>prevalent infections such as<SUP> </SUP>malaria, influenza is clinically<SUP> </SUP>not distinguishable. Therefore, antibody<SUP> </SUP>and cellular responses to<SUP> </SUP>influenza A and B<SUP> </SUP>strains were analyzed in<SUP> </SUP>the sera of schoolchildren<SUP> </SUP>residing in rural and<SUP> </SUP>semi-urban areas of Gabon.<SUP> </SUP>Subsequently, the children received<SUP> </SUP>1 dose each of<SUP> </SUP>influenza vaccine, and their<SUP> </SUP>immune responses at various<SUP> </SUP>intervals after vaccination were<SUP> </SUP>monitored.<SUP> </SUP>
[FONT=helvetica, arial][SIZE=+1]MATERIALS AND METHODS<SUP> </SUP>[/SIZE][/FONT]
Study population. The study was conducted<SUP> </SUP>in and around Lambar?n?<SUP> </SUP>in Gabon, Africa. The<SUP> </SUP>children were from 2<SUP> </SUP>schools, one in a<SUP> </SUP>semi-urban area (Lambar?n?) and<SUP> </SUP>the other in a<SUP> </SUP>rural area (PK15). Their<SUP> </SUP>parents were informed of<SUP> </SUP>the study, and written<SUP> </SUP>informed consents were received<SUP> </SUP>prior to inclusion. The<SUP> </SUP>exclusion criteria were (1)<SUP> </SUP>the absence of informed<SUP> </SUP>consent; (2) the absence<SUP> </SUP>of stool, urine, or<SUP> </SUP>blood samples for parasitological<SUP> </SUP>analysis; and (3) the<SUP> </SUP>presence of any clinical<SUP> </SUP>symptoms. A total of<SUP> </SUP>33 children from the<SUP> </SUP>semi-urban school and 22<SUP> </SUP>children from the rural<SUP> </SUP>school agreed to participate<SUP> </SUP>in the study and<SUP> </SUP>met the inclusion criteria.<SUP> </SUP>The details of the<SUP> </SUP>children are shown in<SUP> </SUP>table 1. The 2 cohorts<SUP> </SUP>of children who were<SUP> </SUP>included in the study<SUP> </SUP>were similar with respect<SUP> </SUP>to age and sex<SUP> </SUP>ratio. Nutritional status was<SUP> </SUP>determined by measuring age-<SUP> </SUP>and sex-adjusted weight, and<SUP> </SUP>by comparing this with<SUP> </SUP>age- and sex-specific values<SUP> </SUP>provided by the Center<SUP> </SUP>for Disease Control and<SUP> </SUP>Prevention (CDC) [22]. For<SUP> </SUP>comparisons, we considered well-nourished<SUP> </SUP>children as being those<SUP> </SUP>with an age- and<SUP> </SUP>sex-adjusted weight >90% of<SUP> </SUP>the median corresponding age-<SUP> </SUP>and sex-adjusted weight of<SUP> </SUP>CDC reference data.<SUP> </SUP>
<TABLE cellSpacing=10><TBODY><TR><TD vAlign=top align=middle>
</TD><TD vAlign=top align=left>[FONT=helvetica, arial][SIZE=-1]Table 1. [/SIZE][/FONT] [FONT=arial,helvetica][SIZE=-1]Study population.[/SIZE][/FONT]</TD></TR></TBODY></TABLE>Among<SUP> </SUP>the cohorts investigated in<SUP> </SUP>this study, 33% of<SUP> </SUP>the children in the<SUP> </SUP>semi-urban school were infected<SUP> </SUP>with <!--Start Italic-->Schistosoma haematobium<!--End Italic-->, whereas 100%<SUP> </SUP>of the children in<SUP> </SUP>the rural school were<SUP> </SUP>infected. These results were<SUP> </SUP>obtained after 3 independent<SUP> </SUP>urine samples were tested.<SUP> </SUP>The prevalence after testing<SUP> </SUP>1 urine sample was<SUP> </SUP>19% in the semi-urban<SUP> </SUP>school and 78% in<SUP> </SUP>the rural schools. The<SUP> </SUP>prevalence of intestinal helminth<SUP> </SUP>infections in the semi-urban<SUP> </SUP>school and in the<SUP> </SUP>rural school was also<SUP> </SUP>significantly different for both<SUP> </SUP><!--Start Italic-->Ascaris lumbricoides<!--End Italic--> (15% and 55%,<SUP> </SUP>respectively; <!--Start Italic-->P<!--End Italic--> = .002)<SUP> </SUP>and <!--Start Italic-->Trichuris trichiuria<!--End Italic--> (12% and<SUP> </SUP>64%, respectively; <!--Start Italic-->P<!--End Italic--> <<SUP> </SUP>.001). These values were<SUP> </SUP>obtained after 2 stool<SUP> </SUP>samples were examined using<SUP> </SUP>the Kato-Katz method.<SUP> </SUP>
Of the<SUP> </SUP>55 children, 12 were<SUP> </SUP>found to be positive<SUP> </SUP>for malaria during the<SUP> </SUP>study. Of these 12,<SUP> </SUP>2 were infected with<SUP> </SUP><!--Start Italic-->Plasmodium malariae<!--End Italic--> and were treated<SUP> </SUP>with chloroquine (10 mg/kg/day<SUP> </SUP>for 2 days and<SUP> </SUP>5 mg/kg/day on the<SUP> </SUP>third day). The remaining<SUP> </SUP>10 children were found<SUP> </SUP>to be positive for<SUP> </SUP><!--Start Italic-->P. falciparum<!--End Italic--> and were treated<SUP> </SUP>when clinical manifestations were<SUP> </SUP>present. Of these 10,<SUP> </SUP>2 presented symptoms of<SUP> </SUP>malaria infection and were<SUP> </SUP>treated with sulfadoxin (25<SUP> </SUP>mg/kg, single dose) and<SUP> </SUP>pyrimethamin (1.25 mg/kg, single<SUP> </SUP>dose), as well as<SUP> </SUP>with artesunate (4 mg/kg/day<SUP> </SUP>for 3 days). An<SUP> </SUP>additional 4 children whose<SUP> </SUP>positivity was reported during<SUP> </SUP>the study were treated<SUP> </SUP>with sulfadoxin and pyrimethamin<SUP> </SUP>because of physical complaints.<SUP> </SUP>
The<SUP> </SUP>study was approved by<SUP> </SUP>the ethics committee of<SUP> </SUP>the International Foundation of<SUP> </SUP>the Albert Schweitzer Hospital<SUP> </SUP>in Lambar?n?.<SUP> </SUP>
Parasitological diagnostics. Infection with <!--Start Italic-->S. haematobium<!--End Italic--><SUP> </SUP>was determined by passing<SUP> </SUP>10 mL of urine<SUP> </SUP>through a filter with<SUP> </SUP>a 10-
Vaccination and sample collection. On day 0,<SUP> </SUP>before vaccination, 3 mL<SUP> </SUP>of heparinated blood was<SUP> </SUP>used for immunological tests.<SUP> </SUP>Children were then vaccinated<SUP> </SUP>against influenza (Begrivac 2004/2005;<SUP> </SUP>Chiron Behring GmbH) and<SUP> </SUP>tetanus (NIPHE). Subsequently, 3<SUP> </SUP>mL of heparinated blood<SUP> </SUP>was drawn on days<SUP> </SUP>2, 4, 7, 14,<SUP> </SUP>and 28 after vaccination,<SUP> </SUP>for use in immunological<SUP> </SUP>assays. At all time<SUP> </SUP>points, the plasma was<SUP> </SUP>frozen and kept at<SUP> </SUP>-20?C, and on all<SUP> </SUP>days except day 28<SUP> </SUP>whole-blood stimulations were performed<SUP> </SUP>to collect supernatants for<SUP> </SUP>cytokine analysis.<SUP> </SUP>
Antibody measurement. For the detection<SUP> </SUP>of serum antibodies against<SUP> </SUP>influenza virus, the haemagglutination<SUP> </SUP>inhibition (HI) assay was<SUP> </SUP>used. The HI assay<SUP> </SUP>was performed in duplicate<SUP> </SUP>according to standard methods<SUP> </SUP>[25, 26], by the<SUP> </SUP>use of turkey erythrocytes<SUP> </SUP>and 4 haemagglutinating units<SUP> </SUP>of the vaccine strains,<SUP> </SUP>which were propagated in<SUP> </SUP>11-day?old embryonated chicken eggs.<SUP> </SUP>Ferret sera raised against<SUP> </SUP>the test antigens were<SUP> </SUP>used as positive controls.<SUP> </SUP>Serum samples were treated<SUP> </SUP>with cholera filtrate to<SUP> </SUP>remove nonspecific anti-haemagglutinins. To<SUP> </SUP>ensure comparability, all serum<SUP> </SUP>samples, collected at different<SUP> </SUP>time points, were tested<SUP> </SUP>at the same time.<SUP> </SUP>For sera with titers<SUP> </SUP>below the detection level,<SUP> </SUP>a value of 5<SUP> </SUP>was assigned. The virus-neutralization<SUP> </SUP>assay was performed according<SUP> </SUP>to standard procedures, as<SUP> </SUP>described previously [27].<SUP> </SUP>
Whole-blood culture and cytokine measurement. Cellular immunological<SUP> </SUP>analysis involved the culturing<SUP> </SUP>of whole blood; 100<SUP> </SUP>
Levels of<SUP> </SUP>interferon (IFN)?
Statistical analysis. Intergroup differences in<SUP> </SUP>age, sex, nutritional status,<SUP> </SUP>and prevalence of parasitic<SUP> </SUP>infections were tested using<SUP> </SUP>Pearson's
[FONT=helvetica, arial][SIZE=+1]RESULTS<SUP> </SUP>[/SIZE][/FONT]
Seroprevalence of antibodies to influenza viruses prior to vaccination. Results obtained with<SUP> </SUP>the HI assay showed<SUP> </SUP>that influenza virus?specific antibodies<SUP> </SUP>were already present in<SUP> </SUP>the majority of sera<SUP> </SUP>before vaccination (figure 1), indicating<SUP> </SUP>that influenza A viruses<SUP> </SUP>of the H1N1 and<SUP> </SUP>H3N2 subtypes and influenza<SUP> </SUP>B virus have been<SUP> </SUP>circulating in Gabon prior<SUP> </SUP>to the present study.<SUP> </SUP>Interestingly, before vaccination, the<SUP> </SUP>antibodies specific to the<SUP> </SUP>H3N2 strain A/Wyoming/3/2003 had<SUP> </SUP>a higher seroprevalance than<SUP> </SUP>did those specific to<SUP> </SUP>the influenza H1N1 and<SUP> </SUP>B strains. The presence<SUP> </SUP>of high titers of<SUP> </SUP>preexisting antibody was confirmed<SUP> </SUP>using an alternative method<SUP> </SUP>for influenza serology. A<SUP> </SUP>virus-neutralization assay was performed<SUP> </SUP>with the sera obtained<SUP> </SUP>from a subset of<SUP> </SUP>19 children from both<SUP> </SUP>study groups, each showing<SUP> </SUP>similar titers: 1593 (range,<SUP> </SUP>160?20,480) and 1481 (range,<SUP> </SUP>80?10,240) for the HI<SUP> </SUP>and neutralization assays, respectively.<SUP> </SUP>Thus, the prevaccination A/Wyoming/3/2003<SUP> </SUP>X147 (H3N2)?specific antibody levels<SUP> </SUP>indicate that an outbreak<SUP> </SUP>of infection caused by<SUP> </SUP>a strain related to<SUP> </SUP>A/Wyoming/3/2003 must have occurred<SUP> </SUP>recently.<SUP> </SUP>
<TABLE cellSpacing=10><TBODY><TR><TD vAlign=top align=middle>

[SIZE=-1](38 kB)[/SIZE]</TD><TD vAlign=top align=left>[FONT=arial,helvetica][SIZE=-1]Figure 1. [/SIZE][/FONT][FONT=arial,helvetica][SIZE=-1]Haemagglutination inhibition (HI) titers<SUP> </SUP>of antibody against the<SUP> </SUP>3 influenza strains present<SUP> </SUP>in the vaccine before<SUP> </SUP>and 14 and 28<SUP> </SUP>days after vaccination. Graphs<SUP> </SUP><!--Start Italic-->A<!--End Italic-->?<!--Start Italic-->C<!--End Italic--> show the individual<SUP> </SUP>data; graphs <!--Start Italic-->D<!--End Italic-->?<!--Start Italic-->F<!--End Italic--> show<SUP> </SUP>the kinetics of the<SUP> </SUP>responses, with the geometric<SUP> </SUP>mean titers per group.<SUP> </SUP>(<!--Start Italic-->A<!--End Italic--> and <!--Start Italic-->D<!--End Italic-->) A/New<SUP> </SUP>Caledonia/20/99, IVR-116 (H1N1); (<!--Start Italic-->B<!--End Italic--><SUP> </SUP>and <!--Start Italic-->E<!--End Italic-->) B/Jiangsu/10/2003; (<!--Start Italic-->C<!--End Italic--><SUP> </SUP>and <!--Start Italic-->F<!--End Italic-->) A/Wyoming/3/2003 X147(H3N2).<SUP> </SUP>The filled triangles and<SUP> </SUP>solid lines represent semi-urban<SUP> </SUP>(sU) subjects; the open<SUP> </SUP>circles and dashed lines<SUP> </SUP>represent rural (R) subjects.<SUP> </SUP>*<!--Start Italic-->P<!--End Italic--> < .05 (Mann-Whitney<SUP> </SUP><!--Start Italic-->U<!--End Italic--> test).[/SIZE][/FONT]
</TD></TR></TBODY></TABLE>
Efficacy of vaccination: antibody production. The antibody responses<SUP> </SUP>to the 3 different<SUP> </SUP>influenza virus strains present<SUP> </SUP>in the vaccine were<SUP> </SUP>determined not only before<SUP> </SUP>but also 14 and<SUP> </SUP>28 days after vaccination<SUP> </SUP>(figure 1). At vaccination, HI<SUP> </SUP>titers of antibody against<SUP> </SUP>the influenza A (H1N1)<SUP> </SUP>strain increased in both<SUP> </SUP>the rural and semi-urban<SUP> </SUP>schoolchildren, but, on day<SUP> </SUP>28, they reached significantly<SUP> </SUP>higher levels in the<SUP> </SUP>semi-urban schoolchildren (figure 1<!--Start Italic-->A<!--End Italic--><SUP> </SUP>and 1<!--Start Italic-->D<!--End Italic-->). Two groups<SUP> </SUP>of children could be<SUP> </SUP>identified, one whose anti-H1N1<SUP> </SUP>titers remained at a<SUP> </SUP>level only slightly higher<SUP> </SUP>than the prevaccination values<SUP> </SUP>(low responders) and another<SUP> </SUP>that showed a prominent<SUP> </SUP>increase in antibody responses<SUP> </SUP>(high responders) (figure 1<!--Start Italic-->A<!--End Italic-->). The<SUP> </SUP>latter group was significantly<SUP> </SUP>larger in the semi-urban<SUP> </SUP>population (figure 2<!--Start Italic-->A<!--End Italic-->), resulting in<SUP> </SUP>the overall higher titers<SUP> </SUP>in the semi-urban children.<SUP> </SUP>Within the semi-urban schoolchildren,<SUP> </SUP>those with helminth infections<SUP> </SUP>(<!--Start Italic-->S. mansoni<!--End Italic-->, <!--Start Italic-->A. lumbricoides<!--End Italic-->, and/or <!--Start Italic-->T. trichiuris<!--End Italic-->)<SUP> </SUP>responded differently to the<SUP> </SUP>H1N1 antibody than did<SUP> </SUP>those without it. Thus,<SUP> </SUP>when only the group<SUP> </SUP>without helminth infections was<SUP> </SUP>compared to the rural<SUP> </SUP>cohort, the difference in<SUP> </SUP>H1N1-specific antibody titers became<SUP> </SUP>highly significant (<!--Start Italic-->P<!--End Italic--> <<SUP> </SUP>.01), at both day<SUP> </SUP>14 and day 28<SUP> </SUP>after vaccination. Indeed, in<SUP> </SUP>terms of percentage of<SUP> </SUP>high responders as well,<SUP> </SUP>it was clear that<SUP> </SUP>helminth-infected children in the<SUP> </SUP>semi-urban area responded more<SUP> </SUP>like rural children (figure 2<!--Start Italic-->A<!--End Italic-->).<SUP> </SUP>In addition, infections with<SUP> </SUP>plasmodia affected anti-H1N1 titers<SUP> </SUP>in rural children but<SUP> </SUP>not in semi-urban children.<SUP> </SUP>As shown in figure 2<!--Start Italic-->B<!--End Italic-->,<SUP> </SUP>only a few rural<SUP> </SUP>children with plasmodia were<SUP> </SUP>high responders when anti-H1N1<SUP> </SUP>antibody titers were considered.<SUP> </SUP>
<TABLE cellSpacing=10><TBODY><TR><TD vAlign=top align=middle>

[SIZE=-1](57 kB)[/SIZE]</TD><TD vAlign=top align=left>[FONT=arial,helvetica][SIZE=-1]Figure 2. [/SIZE][/FONT][FONT=arial,helvetica][SIZE=-1]Influence<SUP> </SUP>of helminth (<!--Start Italic-->A<!--End Italic-->) and<SUP> </SUP>malaria (<!--Start Italic-->B<!--End Italic-->) infection on<SUP> </SUP>antibody responses to influenza<SUP> </SUP>A (H1N1). As shown<SUP> </SUP>in figure 1, antibody responses<SUP> </SUP>to the H1N1 strain<SUP> </SUP>were either low or<SUP> </SUP>high. <!--Start Italic-->A<!--End Italic-->, Percentage of<SUP> </SUP>high responders shown for<SUP> </SUP>the total group of<SUP> </SUP>semi-urban (sU) children (both<SUP> </SUP>infected and uninfected; <!--Start Italic-->gray bars<!--End Italic-->),<SUP> </SUP>for the semi-urban children<SUP> </SUP>without any helminth infection<SUP> </SUP>(sU-; <!--Start Italic-->white bars<!--End Italic-->), for the<SUP> </SUP>semi-urban children with a<SUP> </SUP>helminth (schistosome, ascaris, and/or<SUP> </SUP>trichuris) infection (sU+; <!--Start Italic-->black bars<!--End Italic-->),<SUP> </SUP>and for the rural<SUP> </SUP>(R; <!--Start Italic-->gray bars<!--End Italic-->) children (all<SUP> </SUP>infected). <!--Start Italic-->B<!--End Italic-->, Percentage of<SUP> </SUP>high responders for the<SUP> </SUP>total group of semi-urban<SUP> </SUP>(sU) and rural (R)<SUP> </SUP>children (both infected and<SUP> </SUP>uninfected; <!--Start Italic-->gray bars<!--End Italic-->), for the<SUP> </SUP>semi-urban and rural children<SUP> </SUP>without malaria infection (sU-<SUP> </SUP>and R-; <!--Start Italic-->white bars<!--End Italic-->), and<SUP> </SUP>for the semi-urban and<SUP> </SUP>rural children with malaria<SUP> </SUP>infection (sU+ and R+;<SUP> </SUP><!--Start Italic-->black bars<!--End Italic-->). *<!--Start Italic-->P<!--End Italic--> < .05<SUP> </SUP>(
</TD></TR></TBODY></TABLE>
The antibody<SUP> </SUP>titers specific to the<SUP> </SUP>influenza B strain increased<SUP> </SUP>at vaccination, reaching a<SUP> </SUP>peak at 14 days<SUP> </SUP>after vaccination and slightly<SUP> </SUP>decreasing thereafter (figure 1<!--Start Italic-->B<!--End Italic--><SUP> </SUP>and 1<!--Start Italic-->E<!--End Italic-->). Also, for<SUP> </SUP>this strain, responses were<SUP> </SUP>significantly higher in the<SUP> </SUP>semi-urban children at day<SUP> </SUP>28.<SUP> </SUP>
Compared with the prevaccination<SUP> </SUP>antibody levels specific to<SUP> </SUP>the H1N1 or B<SUP> </SUP>strain of the vaccine,<SUP> </SUP>the prevaccination levels of<SUP> </SUP>antibodies specific to the<SUP> </SUP>influenza A (H3N2) strain<SUP> </SUP>were very high, and<SUP> </SUP>they increased slightly at<SUP> </SUP>vaccination. At day 14,<SUP> </SUP>antibody levels were significantly<SUP> </SUP>higher in the rural<SUP> </SUP>schoolchildren than in the<SUP> </SUP>semi-urban children, but this<SUP> </SUP>difference was no longer<SUP> </SUP>significant at day 28<SUP> </SUP>(figure 1<!--Start Italic-->C<!--End Italic--> and 1<!--Start Italic-->F<!--End Italic-->).<SUP> </SUP>For antibodies specific to<SUP> </SUP>influenza B or H3N2<SUP> </SUP>strains, neither helminth nor<SUP> </SUP>malaria infection influenced the<SUP> </SUP>responses significantly.<SUP> </SUP>
Efficacy of vaccination: cytokine responses. The cytokine response<SUP> </SUP>to influenza was determined<SUP> </SUP>at different time points,<SUP> </SUP>to follow the kinetics<SUP> </SUP>of cellular immune response<SUP> </SUP>development following vaccination (figure 3).<SUP> </SUP>After day 2 following<SUP> </SUP>vaccination, cytokine responses started<SUP> </SUP>to rise. The IL-10<SUP> </SUP>response was early, and<SUP> </SUP>a tight peak was<SUP> </SUP>seen in both rural<SUP> </SUP>and semi-urban schoolchildren at<SUP> </SUP>day 4 (figure 3<!--Start Italic-->A<!--End Italic-->). The<SUP> </SUP>magnitude of the influenza-specific<SUP> </SUP>IL-10 response was significantly<SUP> </SUP>higher in the semi-urban<SUP> </SUP>schoolchildren. The TNF-
<TABLE cellSpacing=10><TBODY><TR><TD vAlign=top align=middle>

[SIZE=-1](44 kB)[/SIZE]</TD><TD vAlign=top align=left>[FONT=arial,helvetica][SIZE=-1]Figure 3. [/SIZE][/FONT][FONT=arial,helvetica][SIZE=-1]Kinetics<SUP> </SUP>of influenza-specific cytokine production<SUP> </SUP>determined by ex vivo<SUP> </SUP>stimulation of whole blood<SUP> </SUP>before and after influenza<SUP> </SUP>vaccination. The mean values<SUP> </SUP>and the 95% confidence<SUP> </SUP>interval of interleukin (IL)?10<SUP> </SUP><!--Start Italic-->(A)<!--End Italic-->, tumor necrosis factor<SUP> </SUP>(TNF)?
</TD></TR></TBODY></TABLE>
[FONT=helvetica, arial][SIZE=+1]DISCUSSION<SUP> </SUP>[/SIZE][/FONT]
The present study<SUP> </SUP>indicates that influenza A<SUP> </SUP>and B viruses circulate<SUP> </SUP>in Gabon and that<SUP> </SUP>the presence of high<SUP> </SUP>levels of A/Wyoming/3/2003 X147<SUP> </SUP>(H3N2)?specific antibodies before vaccination,<SUP> </SUP>as determined by an<SUP> </SUP>HI assay and a<SUP> </SUP>neutralization assay, provides us<SUP> </SUP>with evidence for a<SUP> </SUP>recent outbreak of a<SUP> </SUP>H3N2 virus. Sporadic monitoring<SUP> </SUP>of influenza in other<SUP> </SUP>African countries has revealed<SUP> </SUP>outbreaks of H3N2 virus<SUP> </SUP>in South Africa in<SUP> </SUP>2003 [28], in Madagascar<SUP> </SUP>in 2002 [2], and<SUP> </SUP>in the Democratic Republic<SUP> </SUP>of Congo in 2002<SUP> </SUP>[2]. In addition, influenza<SUP> </SUP>B viruses have been<SUP> </SUP>reported to be circulating<SUP> </SUP>in South Africa, Madagascar,<SUP> </SUP>and Kenya [29, 30].<SUP> </SUP>
In<SUP> </SUP>some of these studies,<SUP> </SUP>a mortality of at<SUP> </SUP>least 3% of cases<SUP> </SUP>was reported, because of<SUP> </SUP>influenza A/Panama/2007/97-like (H3N2) infection,<SUP> </SUP>indicating that influenza can<SUP> </SUP>have a high impact<SUP> </SUP>in African countries as<SUP> </SUP>well [2]. No data<SUP> </SUP>are available on influenza<SUP> </SUP>mortality or morbidity in<SUP> </SUP>Gabon, and, given our<SUP> </SUP>findings, it would not<SUP> </SUP>be surprising if considerable<SUP> </SUP>mortality in the study<SUP> </SUP>area may be attributed<SUP> </SUP>to influenza epidemics. This<SUP> </SUP>is particularly important for<SUP> </SUP>the area we studied?in<SUP> </SUP>fact, for most of<SUP> </SUP>Africa, where malaria is<SUP> </SUP>endemic and where high<SUP> </SUP>fever is often treated<SUP> </SUP>with antimalarials. Thus, influenza<SUP> </SUP>infections in these areas<SUP> </SUP>can lead to considerable<SUP> </SUP>malaria overmedication, on the<SUP> </SUP>one hand, and to<SUP> </SUP>an overestimation of malaria<SUP> </SUP>deaths, on the other.<SUP> </SUP>
In<SUP> </SUP>vaccine-induced antibody responses, considerable<SUP> </SUP>differences between rural and<SUP> </SUP>semi-urban schoolchildren were observed.<SUP> </SUP>The responses to H1N1<SUP> </SUP>and influenza B strains<SUP> </SUP>were higher in the<SUP> </SUP>schoolchildren from the semi-urban<SUP> </SUP>area. Because the prevaccination<SUP> </SUP>titers did not differ<SUP> </SUP>between semi-urban and rural<SUP> </SUP>schoolchildren, it is unlikely<SUP> </SUP>that differences in exposure<SUP> </SUP>to influenza could explain<SUP> </SUP>these results. Why the<SUP> </SUP>schoolchildren in rural areas<SUP> </SUP>would respond differently from<SUP> </SUP>those in semi-urban areas<SUP> </SUP>has yet to be<SUP> </SUP>fully investigated. However, some<SUP> </SUP>vaccines, such as those<SUP> </SUP>for BCG or tetanus,<SUP> </SUP>which were shown to<SUP> </SUP>be effective in nontropical<SUP> </SUP>countries, were found to<SUP> </SUP>induce a weak response<SUP> </SUP>in tropical countries, and<SUP> </SUP>this has been associated<SUP> </SUP>with the presence of<SUP> </SUP>helminth infections [5, 31].<SUP> </SUP>Moreover, although, to our<SUP> </SUP>knowledge, the effect of<SUP> </SUP>helminth infections on the<SUP> </SUP>efficacy of influenza vaccination<SUP> </SUP>has not been investigated<SUP> </SUP>previously, studies on the<SUP> </SUP>efficacy of the cholera<SUP> </SUP>vaccine [19], the BCG<SUP> </SUP>vaccine [32], and tetanus<SUP> </SUP>toxoid vaccine [20, 33]<SUP> </SUP>suggested to us that<SUP> </SUP>immune skewing in response<SUP> </SUP>to vaccines is affected<SUP> </SUP>by preexisting helminth infections.<SUP> </SUP>These studies were performed<SUP> </SUP>in different areas and<SUP> </SUP>considered intestinal helminth [19,<SUP> </SUP>32], filaria, or schistosome<SUP> </SUP>infections [33, 34]. One<SUP> </SUP>of the major differences<SUP> </SUP>between the Gabonese rural<SUP> </SUP>cohort and the Gabonese<SUP> </SUP>semi-urban cohort investigated in<SUP> </SUP>the present study is<SUP> </SUP>the extent of exposure<SUP> </SUP>to parasitic infections, as<SUP> </SUP>shown in table 1. Helminth<SUP> </SUP>infections were shown to<SUP> </SUP>affect H1N1-specific antibody titers<SUP> </SUP>in semi-urban schoolchildren, as<SUP> </SUP>shown in figure 2<!--Start Italic-->A<!--End Italic-->. In<SUP> </SUP>addition, it was found<SUP> </SUP>that malaria-infected schoolchildren in<SUP> </SUP>the rural cohort were<SUP> </SUP>more often low responders<SUP> </SUP>to H1N1 than were<SUP> </SUP>schoolchildren without malaria infection.<SUP> </SUP>This effect was not<SUP> </SUP>found for the semi-urban<SUP> </SUP>cohort, raising the possibility<SUP> </SUP>that malaria infection in<SUP> </SUP>the helminth-infected group (all<SUP> </SUP>schoolchildren in the rural<SUP> </SUP>area were infected with<SUP> </SUP>helminths) has a strong<SUP> </SUP>suppressory effect. Alternatively, malaria<SUP> </SUP>treatment could have affected<SUP> </SUP>the outcome, although several<SUP> </SUP>studies did not find<SUP> </SUP>that malaria treatment has<SUP> </SUP>a negative effect on<SUP> </SUP>outcome of immunization [35http://www.journals.uchicago.edu/JID/journal/issues/v196n11/38547/38547.text.html#rf36?37];<SUP> </SUP>only long-term treatment with<SUP> </SUP>chloroquine has been associated<SUP> </SUP>with impairment of vaccination<SUP> </SUP>efficacy [38]. However, malaria<SUP> </SUP>infection or treatment did<SUP> </SUP>not seem to affect<SUP> </SUP>the titers of antibody<SUP> </SUP>against the influenza A<SUP> </SUP>(H3N2) or the influenza<SUP> </SUP>B strain, nor did<SUP> </SUP>it affect the cytokine<SUP> </SUP>responses in the present<SUP> </SUP>study.<SUP> </SUP>
Another difference noted between<SUP> </SUP>semi-urban and rural schoolchildren<SUP> </SUP>was nutritional status, as<SUP> </SUP>shown in table 1. However,<SUP> </SUP>the differences between antibody<SUP> </SUP>titers could not be<SUP> </SUP>explained by differences in<SUP> </SUP>nutritional status.<SUP> </SUP>
The anti?A/Wyoming/3/2003 X147<SUP> </SUP>(H3N2) antibody levels, which<SUP> </SUP>were very high before<SUP> </SUP>vaccination, increased further after<SUP> </SUP>vaccination. Interestingly, the postvaccination<SUP> </SUP>antibody titers were higher<SUP> </SUP>in the rural schoolchildren,<SUP> </SUP>but at only day<SUP> </SUP>14 after vaccination. Thus,<SUP> </SUP>postvaccination titers of antibody<SUP> </SUP>against a virus strain<SUP> </SUP>that had circulated recently<SUP> </SUP>were no different from,<SUP> </SUP>or even higher than,<SUP> </SUP>those found in urban<SUP> </SUP>schoolchildren. This is different<SUP> </SUP>from what is observed<SUP> </SUP>with postvaccination titers of<SUP> </SUP>antibody against strains that<SUP> </SUP>have not caused a<SUP> </SUP>recent epidemic. The mechanism<SUP> </SUP>behind this is not<SUP> </SUP>clear, but it may<SUP> </SUP>be based on the<SUP> </SUP>differential requirement for activation<SUP> </SUP>of central or effector<SUP> </SUP>memory T cells [39].<SUP> </SUP>
In<SUP> </SUP>terms of cytokine responses,<SUP> </SUP>the semi-urban schoolchildren show<SUP> </SUP>a stronger influenza-specific Th1<SUP> </SUP>response than do the<SUP> </SUP>rural schoolchildren, as determined<SUP> </SUP>by their increased IFN-
Interestingly, there was<SUP> </SUP>a positive correlation (Pearson<SUP> </SUP>correlation coefficient, 0.17; <!--Start Italic-->P<!--End Italic--><SUP> </SUP>= .034) between levels<SUP> </SUP>of IFN-
TNF-
In conclusion,<SUP> </SUP>we report here that<SUP> </SUP>vaccination against the influenza<SUP> </SUP>virus strains that have<SUP> </SUP>not caused a recent<SUP> </SUP>outbreak seems to be<SUP> </SUP>more effective in a<SUP> </SUP>semi-urban population than in<SUP> </SUP>a rural population of<SUP> </SUP>Gabonese schoolchildren. With respect<SUP> </SUP>to cytokine production at<SUP> </SUP>in vitro stimulation of<SUP> </SUP>whole blood by the<SUP> </SUP>vaccine, lower IFN-
[FONT=helvetica, arial]Acknowledgments<SUP> </SUP>[/FONT]
We thank the schoolchildren<SUP> </SUP>of Gabon, for volunteering<SUP> </SUP>for this study; Ludovic<SUP> </SUP>Mewono and Ghyslain Mombo<SUP> </SUP>Ngoma, for help with<SUP> </SUP>sampling; Bart Everts, Nestor<SUP> </SUP>Obiang, and Brigitte Mingombet,<SUP> </SUP>for their technical assistance;<SUP> </SUP>and all the workers<SUP> </SUP>at the Albert Schweitzer<SUP> </SUP>Hospital, for their cooperation.<SUP> </SUP>Furthermore, we thank Ruud<SUP> </SUP>van Beek, for performing<SUP> </SUP>the influenza serology, and<SUP> </SUP>Hae-Won Uh, for help<SUP> </SUP>with the statistical analysis.<SUP> </SUP>
<TABLE cellSpacing=0 cellPadding=0>[FONT=helvetica, arial]References<SUP> </SUP>[/FONT]
<TBODY><TR><TD vAlign=top align=right>1. </TD><TD vAlign=top align=left>Schoub BD, McAnerney JM, Besselaar TG. Regional perspectives on influenza surveillance in Africa. Vaccine 2002; 20:S45?6. First citation in article | PubMed | CrossRef<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>2. </TD><TD vAlign=top align=left>Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 2003; 362:1733?45. First citation in article | PubMed | CrossRef<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>3. </TD><TD vAlign=top align=left>Normile D, Enserink M. Avian influenza: with change in the seasons, bird flu returns. Science 2007; 315:448. First citation in article | PubMed | CrossRef<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>4. </TD><TD vAlign=top align=left>Moszynski P. Africa is ill equipped to fight a bird flu epidemic. BMJ 2006; 332:380. First citation in article | PubMed | CrossRef<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>5. </TD><TD vAlign=top align=left>Baily GV. Tuberculosis prevention trial, Madras. Indian J Med Res 1980; 72(Suppl):1?74. First citation in article | PubMed<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>6. </TD><TD vAlign=top align=left>Rook GAW, Dheda K, Zumla A. Immune systems in developed and developing countries: implications for the design of vaccines that will work where BCG does not. Tuberculosis 2006; 86:152?62. First citation in article | PubMed | CrossRef<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>7. </TD><TD vAlign=top align=left>van der Kleij D, van den Biggelaar AH, Kruize YC, et al. Responses to toll-like receptor ligands in children living in areas where schistosome infections are endemic. J Infect Dis 2004; 189:1044?51. First citation in article | Full Text | PubMed<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>8. </TD><TD vAlign=top align=left>Fell AH, Smith NC. Immunity to asexual blood stages of plasmodium: is resistance to acute malaria adaptive or innate? Parasitology Today 1998; 14:364?9. First citation in article | PubMed | CrossRef<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>9. </TD><TD vAlign=top align=left>Babu S, Blauvelt CP, Kumaraswami V, Nutman TB. Chemokine receptors of T cells and of B cells in lymphatic filarial infection: a role for CCR9 in pathogenesis. J Infect Dis 2005; 191:1018?26. First citation in article | Full Text | PubMed<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>10. </TD><TD vAlign=top align=left>Mahanty S, King CL, Kumaraswami V, et al. IL-4- and IL-5-secreting lymphocyte populations are preferentially stimulated by parasite-derived antigens in human tissue invasive nematode infections. J Immunol 1993; 151:3704?11. First citation in article | PubMed<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>11. </TD><TD vAlign=top align=left>King CL, Medhat A, Malhotra I, et al. Cytokine control of parasite-specific anergy in human urinary schistosomiasis: IL-10 modulates lymphocyte reactivity. J Immunol 1996; 156:4715?21. First citation in article | PubMed<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>12. </TD><TD vAlign=top align=left>Cooper PJ, Chico ME, Sandoval C, et al. Human infection with <!--Start Italic-->Ascaris lumbricoides<!--End Italic--> is associated with a polarized cytokine response. J Infect Dis 2000; 182:1207?13. First citation in article | Full Text | PubMed<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>13. </TD><TD vAlign=top align=left>Jankovic D, Steinfelder S, Kullberg MC, Sher A. Mechanisms underlying helminth- induced Th2 polarization: default, negative or positive pathways? Chem Immunol Allergy 2006; 90:65?81. First citation in article | PubMed<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>14. </TD><TD vAlign=top align=left>Maizels RM, Yazdanbakhsh M. Immune regulation by helminth parasites: cellular and molecular mechanisms. Nat Rev Immunol 2003; 3:733?44. First citation in article | PubMed | CrossRef<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>15. </TD><TD vAlign=top align=left>Redpath S, Ghazal P, Gascoigne NRJ. Hijacking and exploitation of IL-10 by intracellular pathogens. Trends Microbiol 2001; 9:86?92. First citation in article | PubMed | CrossRef<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>16. </TD><TD vAlign=top align=left>Keller CC, Yamo O, Ouma C, et al. Acquisition of hemozoin by monocytes down-regulates interleukin-12 p40 (IL-12p40) transcripts and circulating IL-12p70 through an IL-10-dependent mechanism: in vivo and in vitro findings in severe malarial anemia. Infect Immun 2006; 74:5249?60. First citation in article | PubMed | CrossRef<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>17. </TD><TD vAlign=top align=left>Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Respir Crit Care Med 2006; 173:803?10. First citation in article | PubMed | CrossRef<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>18. </TD><TD vAlign=top align=left>Boettler T, Spangenberg HC, Neumann-Haefelin C, et al. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 2005; 79:7860?7. First citation in article | PubMed | CrossRef<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>19. </TD><TD vAlign=top align=left>Cooper PJ, Chico M, Sandoval C, et al. Human infection with <!--Start Italic-->Ascaris lumbricoides<!--End Italic--> is associated with suppression of the interleukin-2 response to recombinant cholera toxin b subunit following vaccination with the live oral cholera vaccine CVD 103-HgR. Infect Immun 2001; 69:1574?80. First citation in article | PubMed | CrossRef<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>20. </TD><TD vAlign=top align=left>Cooper PJ, Espinel I, Paredes W, Guderian RH, Nutman TB. Impaired tetanus-specific cellular and humoral responses following tetanus vaccination in human onchocerciasis: a possible role for interleukin-10. J Infect Dis 1998; 178:1133?8. First citation in article | PubMed<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>21. </TD><TD vAlign=top align=left>Elias D, Akuffo H, Pawlowski A, Haile M, Schon T, Britton S. <!--Start Italic-->Schistosoma mansoni<!--End Italic--> infection reduces the protective efficacy of BCG vaccination against virulent <!--Start Italic-->Mycobacterium tuberculosis.<!--End Italic--> Vaccine 2005; 23:1326?34. First citation in article | PubMed | CrossRef<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>22. </TD><TD vAlign=top align=left>Ogden CL, Kuczmarski RJ, Flegal KM, et al. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 2002; 109:45?60. First citation in article | PubMed | CrossRef<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>23. </TD><TD vAlign=top align=left>Planche T, Krishna S, Kombila M, et al. Comparison of methods for the rapid laboratory assessment of children with malaria. Am J Trop Med Hyg 2001; 65:599?602. First citation in article | PubMed<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>24. </TD><TD vAlign=top align=left>Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-smear technique in <!--Start Italic-->Schistosomiasis mansoni.<!--End Italic--> Rev Inst Med Trop Sao Paulo 1972; 14:397?400. First citation in article | PubMed<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>25. </TD><TD vAlign=top align=left>Palmer DF, Dowdle WR, Coleman MT, Schild GC. Haemagglutination inhibition test. In: Advanced laboratory techniques for influenza diagnosis: procedural guide. Atlanta: US Dept. of Health and Welfare, 1974:25?62. First citation in article<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>26. </TD><TD vAlign=top align=left>Masurel N, Ophof P, de Jong P. Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus. J Hyg (Lond) 1981; 87:201?9. First citation in article | PubMed<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>27. </TD><TD vAlign=top align=left>Rimmelzwaan GF, Baars M, van Beek R, et al. Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. J Gen Virol 1997; 78:757?65. First citation in article | PubMed<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>28. </TD><TD vAlign=top align=left>Besselaar TG, Botha L, McAnerney JM, Schoub BD. Antigenic and molecular analysis of influenza A (H3N2) virus strains isolated from a localised influenza outbreak in South Africa in 2003. J Med Virol 2004; 73:71?8. First citation in article | PubMed | CrossRef<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>29. </TD><TD vAlign=top align=left>World Health Organization. Recommended composition of influenza virus vaccines for use in the 2005 influenza season. Wkly Epidemiol Rec 2004; 79:369?73. First citation in article | PubMed<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>30. </TD><TD vAlign=top align=left>Gachara G, Ngeranwa J, Magana JM, et al. Influenza virus strains in Nairobi, Kenya. J Clin Virol 2006; 35:117?8. First citation in article | PubMed | CrossRef<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>31. </TD><TD vAlign=top align=left>Prost A, Schlumberger M, Fayet MT. Response to tetanus immunization in onchocerciasis patients. Ann Trop Med Parasitol 1983; 77:83?5. First citation in article | PubMed<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>32. </TD><TD vAlign=top align=left>Elias D, Wolday D, Akuffo H, Petros B, Bronner U, Britton S. Effect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after bacille Calmette-Gu?rin (BCG) vaccination. Clin Exp Immunol 2001; 123:219?25. First citation in article | PubMed | CrossRef<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>33. </TD><TD vAlign=top align=left>Nookala S, Srinivasan S, Kaliraj P, Narayanan RB, Nutman TB. Impairment of tetanus-specific cellular and humoral responses following tetanus vaccination in human lymphatic filariasis. Infect Immun 2004; 72:2598?604. First citation in article | PubMed | CrossRef<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>34. </TD><TD vAlign=top align=left>Sabin EA, Araujo MI, Carvalho EM, Pearce EJ. Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with <!--Start Italic-->Schistosoma mansoni.<!--End Italic--> J Infect Dis 1996; 173:269?72. First citation in article | PubMed<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>35. </TD><TD vAlign=top align=left>Barry M, Patterson JE, Tirrell S, Cullen MR, Shope RE. The effect of chloroquine prophylaxis on yellow fever vaccine antibody response: comparison of plaque reduction neutralization test and enzyme-linked immunosorbent assay. Am J Trop Med Hyg 1991; 44:79?82. First citation in article | PubMed<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>36. </TD><TD vAlign=top align=left>Faucher JF, Binder R, Missinou MA, et al. Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines. Clin Infect Dis 2002; 35:1147?54. First citation in article | Full Text | PubMed<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>37. </TD><TD vAlign=top align=left>Fryauff DJ, Cryz SJ, Widjaja H, et al. Humoral immune response to tetanus-diphtheria vaccine given during extended use of chloroquine or primaquine malaria chemoprophylaxis. J Infect Dis 1998; 177:1762?5. First citation in article | PubMed<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>38. </TD><TD vAlign=top align=left>Fryauff DJ, Church LW, Richards AL, et al. Lymphocyte response to tetanus toxoid among Indonesian men immunized with tetanus-diphtheria during extended chloroquine or primaquine prophylaxis. J Infect Dis 1997; 176:1644?8. First citation in article | PubMed<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>39. </TD><TD vAlign=top align=left>Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004; 22:745?63. First citation in article | PubMed | CrossRef<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>40. </TD><TD vAlign=top align=left>Shi HN, Scott ME, Stevenson MM, Koski KG. Energy restriction and zinc deficiency impair the functions of murine T cells and antigen-presenting cells during gastrointestinal nematode infection. J Nutr 1998; 128:20?7. First citation in article | PubMed<SUP> </SUP></TD></TR><TR><TD vAlign=top align=right>41. </TD><TD vAlign=top align=left>van den Biggelaar AH, van Ree R, Rodrigues LC, et al. Decreased atopy in children infected with <!--Start Italic-->Schistosoma haematobium:<!--End Italic--> a role for parasite-induced interleukin-10. Lancet 2000; 356:1723?7. First citation in article | PubMed | CrossRef<SUP> </SUP></TD></TR>
</TABLE>
http://www.journals.uchicago.edu/JID/journal/issues/v196n11/38547/38547.html